PropertyValue
?:abstract
  • The coronavirus disease 2019 (COVID-19) pandemic has prompted an urgent need for new treatment strategies. No target-specific drugs are currently available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but new drug candidates targeting the viral replication cycle are being explored. A prime target of drug-discovery efforts is the SARS-CoV-2 main protease (M(pro)). The main proteases of different coronaviruses, including SARS-CoV-2, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), share a structurally conserved substrate-binding region that can be exploited to design new protease inhibitors. With the recent reporting of the X-ray crystal structure of the SARS-CoV-2 M(pro), studies to discover M(pro) inhibitors using both virtual and in vitro screening are progressing rapidly. This review focusses on the recent developments in the search for small-molecule inhibitors targeting the SARS-CoV-2 M(pro).
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.drudis.2020.12.005
?:doi
?:journal
  • Drug_Discov_Today
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/f8fe2c99449b554e61eb4ab01c38378288708390.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7724992.xml.json
?:pmcid
?:pmid
?:pmid
  • 33309533.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Potential SARS-CoV-2 main protease inhibitors
?:type
?:year
  • 2020-12-09

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/nxqr58xv>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/nxqr58xv>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all